



Portfolio Amt.	Present Portfolio Value	Cash	Deployed Capital	Returns*
10,00,000	12,88,566	88,566	12,00,000	2,88,566
100%	128.86%	6.87%	93.13%	28.86%

* Returns since inception

Investment Portfolio

Date	Scripts	Reco	Price	Qty	Close	MTM +/-	Status
24-Dec-09	Unichem Lab	Buy	321.50	311	423.35	31,675	Open
23-Feb-10	Cadila Health	Buy	478.85	209	623.75	30,284	Open
26-Feb-10	Sabero Org	Buy	72.10	1,387	72.05	-69	Open
17-Mar-10	Graphite India	Buy	86.10	1,161	97.75	13,526	Open
17-Mar-10	South Indian Bank	Buy	151.00	662	197.40	30,717	Open
22-Mar-10	Naga Agri	Buy	268.40	373	268.35	-19	Open
25-Mar-10	IPCA Labs	Buy	287.45	348	280.00	-2,593	Open
31-Mar-10	Sesa Goa	Buy	464.20	215	370.40	-20,167	Open
07-Apr-10	Shriram EPC	Buy	242.35	413	275.65	13,753	Open
26-Apr-10	GPII	Buy	312.95	320	226.00	-27,824	Open
27-Jul-10	McNally Bharat	Buy	315.25	317	301.30	-4,422	Open
27-Jul-10	LMW	Buy	2,133.00	47	2,025.50	-5,053	Open
					Total	59,809	

Profit/Loss booked

Date	Scripts	Initiating price	Closing price	Qty	Gain /Loss	Total gain/loss	Status
09-Aug-10	C/ F Profits	-	-	-	-	2,28,758	
					Total	2,28,758	

** Booked Profits -BP, Booked Loss- BL, Call Open- Open, Squared Off – SQF, Carried forward loss- C/F Loss & Carried forward profits – C/F Profits

Assumptions for building Emkay Smart Invest

- Portfolio Value is Rs. 10,00,000
- Returns are net of Brokerage
- Date of Inception is 4th August 2009

Emkay Global Financial Services Ltd.

Paragon Center, H -13 -16, 1st Floor, Pandurang Budhkar Marg, Worli, Mumbai – 400 013.
Tel.: 6612 1212 Fax: 6624 2410

DISCLAIMER

Emkay Global Financial Services Ltd. (Emkay) has two separate independent equity research groups: Institutional Equities and Private Client Group. This document has been prepared by Emkay – Private Client Group (Emkay -PCG). Affiliates of Emkay Institutional Group may have issued other reports that are inconsistent with and reach different conclusions from the information presented in this report. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating and target price of the Institutional Equities Research Group of Emkay Global Financial Services Ltd. This document is not for public distribution and has been furnished to you solely for your information and any review, re-transmission, circulation or any other use is strictly prohibited. Persons into whose possession this document may come are required to observe these restrictions. This document is subject to changes without prior notice and is intended only for the person or entity to which it is addressed to and may contain confidential information and/or privileged material. We are not soliciting any action based upon this material. This report is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It is for the general information of clients of Emkay -PCG. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. Emkay-PCG will not treat recipients as customers by virtue of their receiving this report. We have reviewed the report, and in so far as it includes current or historical information, it is believed to be reliable. It should be noted that the information contained herein is from publicly available data or other sources believed to be reliable. Neither Emkay, nor any person connected with it, accepts any liability arising from the use of this document. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for any investment decision. The recipients of this material should rely on their own investigations and take their own professional advice. Price and value of the investments referred to in this material may go up or down. Past performance is not a guide for future performance. Opinions expressed are our current opinions as of the date appearing on this material only. We do not undertake to advise you as to any change of our views expressed in this document. While we would endeavor to update the information herein on a reasonable basis, Emkay, its subsidiaries and associated companies, their directors and employees are under no obligation to update or keep the information current. Also there may be regulatory, compliance, or other reasons that may prevent Emkay and its affiliates from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. Emkay and its affiliates, officers, directors, and employees may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential conflict of interest with respect to any recommendation and related information and opinions. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Analyst's holding in the stocks mentioned in the report: **NIL**
